Systematic review of randomized controlled trials of aspirin and oral anticoagulants in the prevention of graft occlusion and ischemic events after infrainguinal bypass surgery
Mjd. Tangelder et al., Systematic review of randomized controlled trials of aspirin and oral anticoagulants in the prevention of graft occlusion and ischemic events after infrainguinal bypass surgery, J VASC SURG, 30(4), 1999, pp. 701-709
Citations number
41
Categorie Soggetti
Cardiovascular & Respiratory Systems","Cardiovascular & Hematology Research
Purpose: We sought to determine the efficacy of antiplatelet therapy and or
al anticoagulants in maintaining graft patency and preventing ischemic comp
lications in patients after infrainguinal bypass surgery.
Methods: We performed a meta-analysis of randomized controlled trials of as
pirin with or without other antiplatelet therapy and oral anticoagulants af
ter infrainguinal bypass surgery. Outcome measures studied were graft occlu
sion, stroke, myocardial infarction, vascular and total mortality, and the
composite outcome of stroke, myocardial infarction, and vascular mortality.
Results: Five trials of antiplatelet therapy versus placebo were included.
The relative risk (RR) for occlusion was 0.78 (95% CI, 0.64-0.95), For prev
ention of stroke, myocardial infarction, and death, and for the composite o
utcome, no significant effect was measured. Only one trial of oral anticoag
ulants versus control treatment was included. The RR for occlusion was 0.55
(95% CI, 0.30-0.99), and that for amputation was 0.30 (95% CI, 0.10-0.87).
The mortality rate did not differ significantly between the groups. One tr
ial of oral anticoagulant therapy plus aspirin versus aspirin alone in high
-risk patients was included. The RR for occlusion was 0.38 (95% CI, 0.15-0.
95). There were no significant differences for prevention of amputation, my
ocardial infarction, and death between the groups.
Conclusion: Antiplatelet therapy and oral anticoagulants reduce the risk of
graft occlusion. Oral anticoagulant therapy appears to be the more effecti
ve treatment in high-risk patients. Data on the reduction of the risk of st
roke, myocardial infarction, and death are inconclusive. Evidence for the b
eneficial effects of antiplatelet and oral anticoagulant therapy after infr
ainguinal bypass surgery is based on a small number of trials only. There i
s no proof as to which modality is the most effective in the prevention of
graft occlusion and ischemic events in patients after infrainguinal bypass
surgery, which is reason for a randomized comparison of aspirin with oral a
nticoagulants.